- Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health
- The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression
- Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as a panelist for the “Developing Psychedelic Medicine Beyond What We Already Know” forum exploring the potential of once-taboo substances that are gaining an increasing measure of legitimacy and legal recognition.
McKee’s appearance at the Nov. 8 and 9 event billed as “The Largest Psychedelic Medicine Business Event, Ever” gave Tryp an audience that was expected to include participants from a span of up to 140 countries or more in the Sun Belt’s “Magic City,” a world-class hub for trade and tourism. Greg gave an overview of Tryp’s strategy and progress, as well as addressing the crowd in a call to action to continue to emphasize strong support from every angle in order to give psychedelic therapeutic potential the validation it has already proven to deserve.
The Compass data provided proof of rapid and durable responses after three weeks of psilocybin dosing and psychotherapy. Tryp has been actively engaged in developing synthetic psychedelic drugs as the newest sought-after solutions in treating chronic pain and other medical conditions with largely unmet needs. These data continue to validate Tryp’s hypothesis, as Tryp continues to progress towards conducting 4 Phase 2a trials evaluating psilocybin and psychotherapy in fibromyalgia, and eating disorder, pending a favorable review by the FDA.
The company’s submission of an Investigational New Drug application to the U.S. Food and Drug Administration (“FDA”) for its TRP-8802 clinical candidate (https://ibn.fm/mz1Je) marks the latest advancement in its clinical trial that will initially evaluate 25mg oral psilocybin drug candidate, provided by Usona Institute. Compass Pathway’s data revealed the highest response rate among the 25mg dosing cohort, which provides further support for Tryp’s upcoming trial, and Tryp’s trademarked drug candidate, TRP-8803. TRP-8803 will be a synthetic psilocybin drug candidate in which the Company is completing preclinical and bridging studies to perfect its novel route of administration that will lead to more precise control over the patient’s psychedelic experience during the treatment.
Tryp expects to complete a Phase 2a trial for TRP-8802 during the next nine months to determine its safety and initial effectiveness among patients with fibromyalgia. Similarly, TRP-8802 will be evaluated for its performance in treating phantom limb pain and complex regional pain syndrome (“CRPS”). Additional testing in select eating disorders is expected soon pending further review from the FDA.
The clinical trials will be run in combination with psychotherapists trained by Fluence Training.
The company has developed a novel method of administering TRP-8803 to make the experience better for patients. Although testing is still in the pre-clinical stage for it, Tryp expects to benefit from data produced in the TRP-8802 trials as well as data derived directly from TRP-8803 to advance it to phase 2b testing within the next 18 months and on to eventual commercialization. Tryp is committed to driving clinical progress and doing its part to continue to validate the use of psilocybin in select chronic diseases.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.